The FDA has approved Intellia Therapeutics’ one-time in vivo CRISPR medicine for hereditary angioedema (HAE), delivering a Phase III-to-BLA regulatory pathway for lonvoguran ziclumeran (lonvo-z). The approval follows results from the HAELO Phase III trial (NCT06634420), with the drug positioned as an mRNA-lipid nanoparticle (LNP) approach intended to prevent recurrent swelling attacks. In the HAELO study and related discussion, clinicians emphasized the unpredictability and quality-of-life burden of HAE, including psychological stress and life-threatening upper-airway episodes. The approval effectively places a genome-editing modality in a rare-disease treatment category where durability, safety, and long-term impact will be scrutinized by payers and clinicians. For the biotech sector, the decision is a clear signal that in vivo editing—delivered via LNP technology—can clear late-stage efficacy evidence and regulatory review in the US. It also raises expectations for how other CRISPR-enabled programs will be developed and packaged for regulatory endpoints and long-term follow-up. The key near-term questions now shift to real-world durability, immunogenicity monitoring, and uptake in HAE care pathways as clinicians compare a one-time intervention against prophylactic standards of care.